UK AI in Healthcare AI

Growth London

Builds modular lab-automation robotics with orchestration software to run experiments in life-sciences and diagnostics laboratories. Headquartered in London.

Early-stage London

Builds a very large biological database by sampling genetic diversity from nature, then uses it to train generative foundation models for biology and drug discovery. Headquartered in London, with a laboratory in Boston.

Early-stage London

Builds an agentic AI platform over a biomedical knowledge graph to help life-sciences teams accelerate research and drug discovery. Headquartered in London.

Growth Cambridge

Uses AI to discover and repurpose drugs for rare diseases, and runs its own clinical pipeline. A University of Cambridge spinout, headquartered in Cambridge.

Growth London

Applies AI to drug discovery, using models descended from AlphaFold to predict how molecules behave and design new medicines. Headquartered in London as an Alphabet company spun out of DeepMind.

Early-stage London

Applies machine learning and lab automation to discover and optimise therapeutic antibodies, with a pipeline aimed at solid tumours. Headquartered in London.

Seed London

Uses generative AI to design proteins from scratch, aiming to make biology programmable and speed up the discovery of new therapeutics such as antibodies and enzymes. Founded in 2023 by Simon Kohl, a former co-lead of DeepMind's protein-design team and a scientist on AlphaFold2. Headquartered in London.

Early-stage London

An AI drug-discovery company using a "lab-in-the-loop" approach that combines single-cell genomics from patient tissue, laboratory experiments, and machine learning to find new drug targets, starting with bone and immune diseases. Founded in 2019 and headquartered in London.

Early-stage Cambridge

Develops automatic speech recognition and voice AI models covering a wide range of languages and accents, sold to developers and enterprises. Headquartered in Cambridge.